| Literature DB >> 29522571 |
Michael A McCaskey1,2, Brigitte Wirth3, Corina Schuster-Amft2,4, Eling D de Bruin1,5.
Abstract
Sensorimotor training (SMT) is popularly applied as exercise in rehabilitation settings, particularly for musculoskeletal pain. With insufficient evidence on its effect on pain and function, this exploratory randomised controlled trial investigated the potential effects of SMT in rehabilitation of chronic non-specific low back pain. Two arms received 9x30 minutes physiotherapy with added interventions: The experimental arm received 15 minutes of postural SMT while the comparator arm performed 15 minutes of added sub-effective low-intensity training. A treatment blinded tester assessed outcomes at baseline 2-4 days prior to intervention, pre- and post-intervention, and at 4-week follow-up. Main outcomes were pain and functional status assessed with a 0-100mm visual analogue scale and the Oswestry Disability Questionnaire. Additionally, postural control was analysed using a video-based tracking system and a pressure plate during perturbed stance. Robust, nonparametric multivariate hypothesis testing was performed. 22 patients (11 females, aged 32 to 75 years) with mild to moderate chronic pain and functional limitations were included for analysis (11 per arm). At post-intervention, average values of primary outcomes improved slightly, but not to a clinically relevant or statistically significant extent. At 4-week follow-up, there was a significant improvement by 12 percentage points (pp) on the functional status questionnaire in the SMT-group (95% confidence intervall (CI) = 5.3pp to 17.7pp, p < 0.001) but not in the control group (4 pp improvement, CI = 11.8pp to 19.2pp). However, group-by-time interaction effects for functional status (Q = 3.3, 19 p = 0.07) and pain (Q = 0.84, p = 0.51) were non-significant. Secondary kinematic outcomes did not change over time in either of the groups. Despite significant improvement of functional status after SMT, overall findings of this exploratory study suggest that SMT provides no added benefit for pain reduction or functional improvement in patients with moderate chronic non-specific low back pain. TRIAL REGISTRATION: ClinicalTrials.gov NCT02304120 and related study protocol, DOI: 10.1186/1471-2474-15-382.Entities:
Mesh:
Year: 2018 PMID: 29522571 PMCID: PMC5844549 DOI: 10.1371/journal.pone.0193358
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flow chart.
BL = baseline assessment; T0 = pre-test, T1 = post-test, T2 = 4-week follow-up. SMT = sensorimotor training group; SLT = sub-effective low-intensity endurance training group; PT = standard physiotherapy.
Mean, standard deviation and range values for characteristics of the study population.
| Units | Experimental group | Control group | |
|---|---|---|---|
| Gender | f/m | 6/5 | 5/6 |
| Age (range) | years | 55 (32–75) | 54 (33–67) |
| Height (SD) | cm | 172.4 (11.1) | 172.8 (7.9) |
| Weight (SD) | kg | 71.8 (10.5) | 72.2 (12.7) |
| Activity level | 1/2/3 | 4/4/3 | 3/6/2 |
| VAS at BL (SD) | % | 23.9 (7.1) | 25.9 (22.8) |
| ODI at BL (SD) | % | 19.8 (5.3) | 17.6 (10.5) |
*PAPRICA defined activity levels (1 = inactive, 2 = moderately active, 3 = trained); VAS = visual analogue scale for pain; ODI = Oswestry Disability Index; BL = Baseline.
Main results of primary and secondary outcomes at 4 measurement events.
| Control | Experimental | p | ||
|---|---|---|---|---|
| Primary outcomes | ||||
| ODI [%] | ||||
| BL | 16 (4.8–27.2) | 20 (14.4–25.0) | 4 (−11.5–18.9) | 0.5 |
| T0 | 18 (4.1–31.3) | 16 (8.9–23.7) | 2 (−20.1–17.2) | 0.8 |
| T1 | 11 (5.7–16.0) | 13 (4.9–21.4) | 2 (−9.2–13.8) | 0.6 |
| T2 | 12 (7.1–17.5) | 8 (2.3–14.2) | 4 (−13.1–5.0) | 0.2 |
| VAS | ||||
| [mm] | ||||
| BL | 20.0 (12.0–27.5) | 25.0 (17.0–32.5) | 5.0 (−7.5–17.5) | 0.3 |
| T0 | 22.0 (9.5–35.0) | 25.0 (18.5–31.5) | 3.0 (−14.5–20.0) | 0.6 |
| T1 | 13.5 (4.0–23.5) | 19.0 (6.5–31.5) | 5.5 (−13.5–23.5) | 0.4 |
| T2 | 15.5 (9.0–22.0) | 15.5 (3.5–28.0) | 0.0 (−16.5–17.0) | 1.0 |
| Secondary outcomes | ||||
| UI [ratio] | ||||
| BL | 0.53 (0.42–0.64) | 0.46 (0.14–0.78) | −0.07 (−0.50–0.36) | 0.62 |
| T0 | 0.38 (0.08–0.69) | 0.41 (0.09–0.72) | 0.02 (−0.48–0.53) | 0.89 |
| T1 | 0.51 (0.22–0.80) | 0.55 (0.26–0.85) | 0.04 (−0.43–0.52) | 0.79 |
| FU | 0.43 (0.29–0.57) | 0.47 (0.12–0.82) | 0.04 (−0.44–0.51) | 0.80 |
| CEA [cm] | ||||
| BL | 5.12 (3.04–7.20) | 6.79 (4.80–8.79) | 1.68 (−1.63–4.98) | 0.17 |
| T0 | 2.34 (0.68–4.00) | 3.59 (0.74–6.45) | 1.25 (−2.68–5.19) | 0.36 |
| T1 | 3.26 (1.71–4.81) | 4.66 (1.47–7.86) | 1.40 (−2.93–5.73) | 0.35 |
| FU | 2.34 (1.64–3.03) | 4.80 (1.92–7.67) | 2.46 (−1.39–6.31) | 0.08 |
| ApEn [ratio] | ||||
| BL | 0.30 (0.24–0.37) | 0.29 (0.26–0.32) | 0.01 (−0.10–0.08) | 0.69 |
| T0 | 0.28 (0.22–0.34) | 0.24 (0.16–0.31) | 0.05 (−0.16–0.06) | 0.23 |
| T1 | 0.28 (0.24–0.32) | 0.27 (0.23–0.31) | 0.01 (−0.08–0.05) | 0.60 |
| FU | 0.27 (0.22–0.33) | 0.21 (0.17–0.26) | 0.06 (−0.14–0.03) | 0.07 |
Trimmed means (T-mean, 20%) of primary and secondary outcomes at baseline (BL), pre- and post intervention (T0 and T1), and 4-week follow-up (T2). δ = mean difference between groups, CI and CI = upper and lower 95% confidence interval, p = p-value of between-difference.
*Significant within-change since BL (p < 0.001).